Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions

Scholar Rock Holding now carries a slightly higher modelled fair value, shifting from US$59.31 to US$62.06. This places it in line with the low to mid US$60s price targets cited in recent research. Street commentary around the Isembyld approval, updated adoption assumptions and the US$63 JPMorgan target helps explain why analysts are comfortable anchoring expectations around this new level. As you read on, you will see how these evolving targets and the surrounding narrative might shape your view on Scholar Rock Holding.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Scholar Rock Holding.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Several firms, including BMO Capital, Citi, Truist, Raymond James, Evercore ISI, Piper Sandler, Wedbush and H.C. Wainwright, have moved Scholar Rock Holding price targets into the US$70s and even low US$80s, citing the FDA approval of ISEMBYLD and the breadth of the label.

• Analysts at BMO Capital and Raymond James highlight ISEMBYLD as a muscle targeted treatment used on top of SMN2 therapies. Their commentary around commercial launch details, demand from specialists and supply preparedness is cited as key support for their higher targets.

• Wedbush explicitly references Scholar Rock Holding as a potential acquisition candidate for a larger pharma with an existing neuromuscular or rare disease franchise, reflecting interest in the SMA franchise value.

• Firms such as Truist and Citi emphasize that the approval came with a broad label that aligns with expectations. They reference broad uptake assumptions in combination with SMN2 regulators, which underpin their updated models.

🐻 Bearish Takeaways

• Barclays has downgraded Scholar Rock Holding to Equal Weight while still lifting its target to US$58. The firm argues that much of the Isembyld approval outcome was already assumed and that the risk or reward now appears more balanced on valuation.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 3 risks for Scholar Rock Holding. See which could impact your investment.

How This Changes the Fair Value For Scholar Rock Holding

• Fair Value has moved from US$59.31 to US$62.06, reflecting a modest uplift in the modelled estimate for Scholar Rock Holding.

• The revenue growth assumption is now described as very large, shifting from 638.02% to 684.10% in the long-term model.

• Net profit margin has eased from 18.92% to 17.73% in the updated assumptions.

• The future P/E has moved from 140.37x to 134.46x in the updated valuation work.

• The discount rate has edged higher from 7.22% to 7.51% in the latest analysis.